A novel platform for radioimmunotherapy: extracorporeal depletion of biotinylated and (90)y-labeled rituximab in patients with refractory B-cell lymphoma.
- Oncology and Pathology, MV
- Medical Radiation Physics, Lund
Publishing year: 2005
Publication/Series: Cancer Biotherapy & Radiopharmaceuticals
Document type: Journal article
Publisher: Mary Ann Liebert, Inc.
- Cancer and Oncology
- ISSN: 1557-8852